CVRx Reports First Quarter 2026 Financial and Operating Results
CVRx, Inc. reported a 20% increase in total revenue for Q1 2026 to $14.8 million, driven by a 22% growth in U.S. revenue attributed to expanded sales territories and increased awareness of its Barostim device. The company initiated the BENEFIT-HF clinical trial with the first site activated and patient enrolled in Q2 2026. CVRx maintained its 2026 …